Cargando…

Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor

Although respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants and young children, attempts to develop an effective therapy have so far proved unsuccessful. Here we report the preclinical profiles of PC786, a potent nonnucleoside RSV L protein pol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coates, Matthew, Brookes, Daniel, Kim, Young-In, Allen, Heather, Fordyce, Euan A. F., Meals, Elizabeth A., Colley, Thomas, Ciana, Claire-Lise, Parra, Guillaume F., Sherbukhin, Vladimir, Stockwell, Jennifer A., Thomas, Jennifer C., Hunt, S. Fraser, Anderson-Dring, Lauren, Onions, Stuart T., Cass, Lindsey, Murray, Peter J., Ito, Kazuhiro, Strong, Pete, DeVincenzo, John P., Rapeport, Garth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2017
Materias:	Antiviral Agents
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571287/ https://www.ncbi.nlm.nih.gov/pubmed/28652242 http://dx.doi.org/10.1128/AAC.00737-17

Ejemplares similares

Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study
por: DeVincenzo, John, et al.
Publicado: (2020)

A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein
por: DeVincenzo, John, et al.
Publicado: (2020)

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
por: Detalle, Laurent, et al.
Publicado: (2015)

Discovery of a Novel Respiratory Syncytial Virus Replication Inhibitor
por: Wang, Li, et al.
Publicado: (2021)

Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages
por: Sake, Svenja M., et al.
Publicado: (2022)

A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading
por: Gaillard, Vanessa, et al.
Publicado: (2017)

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
por: Griffin, M. Pamela, et al.
Publicado: (2017)

Targeting the Respiratory Syncytial Virus N(0)-P Complex with Constrained α-Helical Peptides in Cells and Mice
por: Galloux, Marie, et al.
Publicado: (2020)

Late therapeutic intervention with a respiratory syncytial virus L‐protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium
por: Brookes, Daniel W, et al.
Publicado: (2018)

Src Family Kinase Inhibitors Block Translation of Alphavirus Subgenomic mRNAs
por: Broeckel, Rebecca, et al.
Publicado: (2019)

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers
por: Kankam, Martin K., et al.
Publicado: (2021)

Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region
por: Han, Kelong, et al.
Publicado: (2022)

Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/Ritonavir
por: Schnell, Gretja, et al.
Publicado: (2015)

Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir
por: Krishnan, Preethi, et al.
Publicado: (2015)

Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus
por: Levendosky, Keith, et al.
Publicado: (2015)

Multipurpose Prevention Approaches with Antiretroviral-Based Formulations
por: Jean-Pierre, Ninochka, et al.
Publicado: (2016)

Structure-Based Design and Antigenic Validation of Respiratory Syncytial Virus G Immunogens
por: Nuñez Castrejon, Ana M., et al.
Publicado: (2022)

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir
por: Ng, Teresa I., et al.
Publicado: (2017)

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir
por: Badri, Prajakta S., et al.
Publicado: (2015)

Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection
por: Burdette, Dara, et al.
Publicado: (2022)

Investigating the Influence of Ribavirin on Human Respiratory Syncytial Virus RNA Synthesis by Using a High-Resolution Transcriptome Sequencing Approach
por: Aljabr, Waleed, et al.
Publicado: (2016)

Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir
por: Krishnan, Preethi, et al.
Publicado: (2016)

Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials
por: Krishnan, Preethi, et al.
Publicado: (2018)

Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan
por: Krishnan, Preethi, et al.
Publicado: (2018)

SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients
por: Dieterich, Douglas, et al.
Publicado: (2014)

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir
por: Ng, Teresa I., et al.
Publicado: (2017)

Characterization of Influenza B Virus Variants with Reduced Neuraminidase Inhibitor Susceptibility
por: Farrukee, R., et al.
Publicado: (2018)

Antiprion Activity of DB772 and Related Monothiophene- and Furan-Based Analogs in a Persistently Infected Ovine Microglia Culture System
por: Dinkel, Kelcey D., et al.
Publicado: (2016)

A Photoactivable Natural Product with Broad Antiviral Activity against Enveloped Viruses, Including Highly Pathogenic Coronaviruses
por: Meunier, Thomas, et al.
Publicado: (2022)

Protamine Sulfate Is a Potent Inhibitor of Human Papillomavirus Infection In Vitro and In Vivo
por: Young, Jesse M., et al.
Publicado: (2022)

A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques
por: Su, Jonathan T., et al.
Publicado: (2020)

Polymerase Activity, Protein-Protein Interaction, and Cellular Localization of the Usutu Virus NS5 Protein
por: Albentosa-González, L., et al.
Publicado: (2019)

The Small-Compound Inhibitor K22 Displays Broad Antiviral Activity against Different Members of the Family Flaviviridae and Offers Potential as a Panviral Inhibitor
por: García-Nicolás, Obdulio, et al.
Publicado: (2018)

A Continuous Enzyme-Coupled Assay for Triphosphohydrolase Activity of HIV-1 Restriction Factor SAMHD1
por: Arnold, Laurence H., et al.
Publicado: (2014)

Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine
por: Jeffrey, Jerry L., et al.
Publicado: (2022)

Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses
por: Vigil, Adam, et al.
Publicado: (2018)

Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
por: Ford, S. L., et al.
Publicado: (2017)

Safety and Pharmacokinetics of LHF-535, a Potential Treatment for Lassa Fever, in Healthy Adults
por: Amberg, Sean M., et al.
Publicado: (2022)

TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells
por: Bam, Rujuta A., et al.
Publicado: (2016)

Hepatitis B Virus Capsid Assembly Modulators, but Not Nucleoside Analogs, Inhibit the Production of Extracellular Pregenomic RNA and Spliced RNA Variants
por: Lam, Angela M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mjndoplmc1233bhist0eva23v2